tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Nature’s Sunshine Buys Out Fosun Pharma’s Joint Ventures

Story Highlights
Nature’s Sunshine Buys Out Fosun Pharma’s Joint Ventures

Elevate Your Investing Strategy:

An update from Nature’s Sunshine Products ( (NATR) ) is now available.

On June 27, 2025, Fosun Pharma sold a significant portion of its shares in Nature’s Sunshine Products, reducing its ownership below 5%. Consequently, on June 30, 2025, Nature’s Sunshine Products agreed to repurchase Fosun Pharma’s interests in their joint ventures in Hong Kong and Shanghai for a total of $7 million, subject to regulatory approvals in China.

The most recent analyst rating on (NATR) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Nature’s Sunshine Products stock, see the NATR Stock Forecast page.

Spark’s Take on NATR Stock

According to Spark, TipRanks’ AI Analyst, NATR is a Outperform.

Nature’s Sunshine Products displays strong financial health, robust cash flow, and a stable balance sheet, contributing to a solid foundation in the packaged foods industry. The stock exhibits positive technical momentum, although it’s nearing overbought levels. Valuation is less attractive due to a high P/E ratio and no dividend yield, but recent earnings results and strategic expansion efforts in key markets provide reasons for optimism. Challenges in North America and macroeconomic uncertainties are noted, but overall, the stock is well-positioned for future growth.

To see Spark’s full report on NATR stock, click here.

More about Nature’s Sunshine Products

Nature’s Sunshine Products, Inc. operates in the health and wellness industry, focusing on the marketing and distribution of nutritional and personal care products. The company has a market focus in China through its joint ventures with Fosun Pharma.

Average Trading Volume: 78,368

Technical Sentiment Signal: Strong Buy

Current Market Cap: $287.8M

For detailed information about NATR stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1